

Matthew S Davids

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9349961/publications.pdf>

Version: 2024-02-01

169
papers

9,346
citations

87401

40
h-index

46524

93
g-index

169
all docs

169
docs citations

169
times ranked

10903
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1271-1281.	0.6	18
2	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
3	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
4	Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
5	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	0.6	29
6	A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3
7	Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. <i>Haematologica</i> , 2022, 107, 984-987.	1.7	19
8	Idelalisib in indolent NHL – has it finally found its niche?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1029-1030.	0.6	0
9	miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021, 137, 2481-2494.	0.6	37
10	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	3.3	25
11	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	1.7	7
12	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	0.6	24
13	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021, 397, 892-901.	6.3	260
14	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	0.4	3
15	Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2342-2351.	0.6	8
16	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	3.2	38
17	Twists and turns from tumor profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006089.	0.5	0
18	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	0.6	22

#	ARTICLE	IF	CITATIONS
19	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	7.7	31
20	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K \hat{I} inhibitor idelalisib. <i>Haematologica</i> , 2021, 106, 2995-2999.	1.7	14
21	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	1.7	15
22	The redox-senescence axis and its therapeutic targeting. <i>Redox Biology</i> , 2021, 45, 102032.	3.9	34
23	Integrated safety analysis of umbralisib, a dual PI3K \hat{I} /CK1 $\hat{\mu}$ inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	2.5	13
24	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.	5.1	53
25	Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	2.0	17
26	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	1.7	4
27	Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1532-1544.	0.5	8
28	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	3.3	14
29	Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2633-2633.	0.6	1
30	A Phase I Trial of PI3K $\hat{\mu}$ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). <i>Blood</i> , 2021, 138, 3558-3558.	0.6	3
31	Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. <i>Blood</i> , 2021, 138, 1553-1553.	0.6	2
32	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	0.6	4
33	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	0.6	4
34	BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). <i>Blood</i> , 2021, 138, 3742-3742.	0.6	4
35	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	0.6	8
36	Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab. <i>Blood</i> , 2021, 138, 1201-1201.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 4, 21-23.	0.3	0
38	Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 1955-1974.e15.	1.1	15
39	Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. <i>Nucleic Acids Research</i> , 2020, 48, 12727-12745.	6.5	27
40	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect Â® CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	0.4	2
41	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
42	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
43	Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. <i>Pharmacoeconomics</i> , 2020, 38, 941-951.	1.7	11
44	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
45	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	6.3	302
46	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	3.2	31
47	Systematic literature review of the global burden of illness of mantle cell lymphoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 843-852.	0.9	3
48	<i>Pneumocystis jirovecii</i> pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020, 4, 1458-1463.	2.5	28
49	Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. <i>Lancet, The</i> , 2020, 395, 1234-1236.	6.3	1
50	Breaking through BCL-2 inhibition in CLL. <i>Blood</i> , 2020, 135, 709-711.	0.6	6
51	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 35-37.	0.6	16
52	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. <i>Blood</i> , 2020, 136, 15-17.	0.6	9
53	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020, 136, 46-47.	0.6	13
54	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.	0.6	16

#	ARTICLE	IF	CITATIONS
55	A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 51-52.	0.6	4
56	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. <i>Blood</i> , 2020, 136, 29-30.	0.6	0
57	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-35.	0.6	1
58	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	0.6	3
59	Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition. <i>Blood</i> , 2020, 136, 20-20.	0.6	0
60	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
61	CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
62	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
63	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
64	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 527-530.	0.6	14
65	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	2.2	60
66	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	0.6	81
67	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
68	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	7.7	224
69	Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. <i>JAAD Case Reports</i> , 2019, 5, 401-405.	0.4	10
70	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	0.6	145
71	BCL-2 Inhibitors, Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 401-409.	1.0	25
72	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	2.2	98

#	ARTICLE	IF	CITATIONS
73	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cyto-reduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	0.6	3
74	Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. <i>Blood</i> , 2019, 134, 265-265.	0.6	4
75	Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na ⁺ Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven). <i>Blood</i> , 2019, 134, 4320-4320.	0.6	7
76	Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. <i>Blood</i> , 2019, 134, 4741-4741.	0.6	8
77	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	0.6	1
78	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3965-3965.	0.6	1
79	Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vencabrutinib, in B-Cell Malignancies. <i>Blood</i> , 2019, 134, 3041-3041.	0.6	23
80	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. <i>Blood</i> , 2019, 134, 807-807.	0.6	2
81	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	0.6	6
82	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	0.6	28
83	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na ⁺ Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	0.6	3
84	An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4716-4716.	0.6	1
85	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. <i>Blood</i> , 2018, 131, 1987-1989.	0.6	42
86	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. <i>Cancer Imaging</i> , 2018, 18, 13.	1.2	3
87	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2018, 131, 1073-1080.	0.6	26
88	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	0.6	122
89	A complex case of ibrutinib treatment for a <sc>CLL</sc> patient on haemodialysis. <i>British Journal of Haematology</i> , 2018, 181, 854-857.	1.2	4
90	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	5.1	314

#	ARTICLE	IF	CITATIONS
91	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
92	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	0.6	261
93	A new triple threat to CLL. <i>Blood</i> , 2018, 132, 1547-1548.	0.6	0
94	The rise of apoptosis: targeting apoptosis in hematologic malignancies. <i>Blood</i> , 2018, 132, 1248-1264.	0.6	107
95	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
96	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127
97	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018, 3, .	2.3	39
98	The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax. <i>Blood</i> , 2018, 132, 4393-4393.	0.6	7
99	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	0.6	5
100	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2888-2888.	0.6	22
101	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	0.6	2
102	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.	0.6	2
103	A Phase I/IIb Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	0.6	10
104	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 893-893.	0.6	4
105	Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies. <i>Blood</i> , 2018, 132, 3146-3146.	0.6	1
106	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	0.6	0
107	Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5868-5868.	0.6	0
108	Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5848-5848.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , 2017, 18, 230-240.	5.1	287
110	The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 11-19.	1.2	44
111	Venetoclax for the treatment of patients with chronic lymphocytic leukemia. <i>Future Oncology</i> , 2017, 13, 1223-1232.	1.1	7
112	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	2.9	39
113	<i>i>IGHV</i> mutational status testing in chronic lymphocytic leukemia. <i>American Journal of Hematology</i>, 2017, 92, 1393-1397.</i>	2.0	47
114	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	7.7	164
115	Targeting BCL-2 in B-cell lymphomas. <i>Blood</i> , 2017, 130, 1081-1088.	0.6	58
116	Safety profiles of novel agent therapies in CLL. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 354-357.	0.9	1
117	How should we sequence and combine novel therapies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 346-353.	0.9	18
118	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
119	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneic HCT: A CIBMTR Report. <i>Blood</i> , 2017, 130, 667-667.	0.6	2
120	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. <i>BJR case Reports</i> , 2016, 2, 20150271.	0.1	3
121	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-methylated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 978-983.	2.0	14
122	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
123	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	0.6	242
124	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	0.6	259
125	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016, 128, 1609-1613.	0.6	85
126	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	13.9	488

#	ARTICLE	IF	CITATIONS
127	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	5.8	285
128	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
129	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
130	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	0.6	12
131	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	0.6	15
132	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. <i>Blood</i> , 2016, 128, 4045-4045.	0.6	1
133	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016, 128, 4346-4346.	0.6	2
134	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	0.6	7
135	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	0.6	48
136	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	0.6	10
137	The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 ^{hi} and CXCR4 ^{lo} WHIM ^{hi} mutated Waldenstrom macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 170, 134-138.	1.2	63
138	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	1.2	19
139	BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. <i>Clinical Cancer Research</i> , 2015, 21, 5021-5029.	3.2	76
140	The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 18-27.	1.2	2
141	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. <i>Blood</i> , 2015, 126, 490-490.	0.6	15
142	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. <i>Future Oncology</i> , 2014, 10, 957-967.	1.1	136
143	Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2675-2677.	0.6	2
144	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15

#	ARTICLE	IF	CITATIONS
145	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2014, 150, 280.	2.0	83
146	Boldly Targeting Kinases without mutations. <i>Blood</i> , 2014, 123, 1119-1121.	0.6	6
147	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	0.6	32
148	Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 224-9.	0.3	25
149	Phosphoinositide 3-Kinase Inhibition in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 329-339.	0.9	8
150	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. <i>Leukemia and Lymphoma</i> , 2013, 54, 1823-1825.	0.6	23
151	ABT-199: Taking Dead Aim at BCL-2. <i>Cancer Cell</i> , 2013, 23, 139-141.	7.7	83
152	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. <i>Blood</i> , 2013, 122, 1789-1789.	0.6	32
153	Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients. <i>Blood</i> , 2013, 122, 4170-4170.	0.6	8
154	Therapeutic Targeting of the Bcl2 Family. <i>Blood</i> , 2013, 122, SCI-42-SCI-42.	0.6	0
155	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 3501-3509.	0.6	117
156	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2362-2370.	0.6	71
157	Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3127-3135.	0.8	236
158	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	0.6	18
159	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012, 120, 3923-3923.	0.6	3
160	Cell Trafficking in Chronic Lymphocytic Leukemia. <i>Open Journal of Hematology</i> , 2012, 3, 1.	0.4	56
161	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3920-3920.	0.6	0
162	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012, 120, 1980-1980.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. <i>Blood</i> , 2011, 118, 2683-2683.	0.6	3
164	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 974-974.	0.6	2
165	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1438-1438.	0.6	0
166	MEDICAL MANAGEMENT OF RADIATION VICTIMS IN THE UNITED STATES. <i>Health Physics</i> , 2010, 98, 833-837.	0.3	6
167	The molecular pathogenesis of myelodysplastic syndromes. <i>Cancer Biology and Therapy</i> , 2010, 10, 309-319.	1.5	38
168	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1436-1441.	2.0	9
169	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. <i>Blood</i> , 2010, 116, 692-692.	0.6	0